Guangdong Hybribio Biotech Unit Gets China Nod for HPV Diagnostic Kit
China's medical products administrator approved Guangdong Hybribio Biotech (SHE:300639) subsidiary Guangzhou Kaipu Pharmaceutical Technology's medical device registration for its SOX1 and PAX1 gene methylation detection kit.
The kits are used to diagnose 12 high-risk human papillomavirus (HPV) genotypes in females, according to a Wednesday filing with the Shenzhen Stock Exchange.
The permit is valid for five years.
Price (RMB): ¥5.28, Change: ¥+0.020, Percent Change: +0.38%